Leading Indications
Our scientific advisory board — including former Heart Failure Society of America presidents — has directly shaped our Phase 2 study design and clinical protocol.
Co-founder of ViCardia Therapeutics. Four-time founder/executive of VC-backed medtech and healthcare companies, twice serving as CEO — including one completed IPO. Former CEO of the Ischemia Research and Education Foundation, a cardiovascular research institute at UCSF.
Education University of Colorado Boulder · UC Law San Francisco
Track record 4x VC-backed company builder
“MitoForge is the key to treating mitochondrial metabolic dysfunction across chronic and rare disease.”
Because mitochondrial dysfunction is a unifying pathology, the platform’s modular architecture extends from our lead cardiovascular program into a broader set of tissue-directed opportunities.
Restoring mitochondrial function in heart failure and cardiovascular disease.
Expanding impact across genetically defined mitochondrial diseases.
Targeting mitochondrial dysfunction in selected neurologic diseases.
Treating mitochondrial dysfunction across the heart–kidney axis.
Correcting the metabolic deficit upstream of insulin resistance.
Exploring mitochondrial support for muscle and cardiac performance in long-duration spaceflight.
Target tissue rationale: heart, muscle and cerebrovascular endothelium (CNS) are post-mitotic — mitochondrial DNA damage accumulates over time rather than diluting through cell division, which is what makes these tissues a natural fit for the platform.
Restoring mitochondrial function in heart failure and cardiovascular disease
ADHF · HFrEF / HFpEF · Stage B pre-heart failure
Parkinson’s · Alzheimer’s · ALS · Huntington’s
Correcting the metabolic deficit upstream of insulin resistance.
Expanding impact across genetically defined mitochondrial diseases.
Friedreich’s Ataxia · Barth Syndrome · MELAS
CKD · Cardio-renal syndrome
Exploring mitochondrial support for muscle and cardiac performance in long-duration spaceflight.
Muscle atrophy · Cardiac deconditioning
Target tissue rationale: heart, muscle and cerebrovascular endothelium (CNS) are post-mitotic — mitochondrial DNA damage accumulates over time rather than diluting through cell division, which is what makes these tissues a natural fit for the platform.
A clinical-stage biopharmaceutical company developing MitoForge™, a precision intracellular delivery platform for mitochondrial metabolic dysfunction.
© 2026 ViCardia Therapeutics, Inc. All Rights Reserved.
MitoForge™ and Precision Intracellular Delivery™ are trademarks of ViCardia Therapeutics, Inc.
